Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Abiraterone
Drug ID BADD_D00014
Description Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.
Indications and Usage Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.
Marketing Status Not Available
ATC Code Not Available
DrugBank ID DB05812
KEGG ID Not Available
MeSH ID C089740
PubChem ID 132971
TTD Drug ID D02STN
NDC Product Code 17337-0082; 30007-838; 42291-073; 60687-455; 69238-1165; 42291-024; 69238-1754; 54893-0070
Synonyms abiraterone | 17-(3-pyridyl)androsta-5,16-dien-3beta-ol | CB-7598 | CB 7598 | CB7598
Chemical Information
Molecular Formula C24H31NO
CAS Registry Number 154229-19-3
SMILES CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Eating disorder14.03.01.008; 19.09.01.0080.008090%Not Available
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.001--Not Available
Eczema23.03.04.006--
Electrocardiogram QT prolonged13.14.05.004--
Electrolyte imbalance14.05.01.0020.006619%Not Available
Emotional disorder19.04.02.005--Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Eructation07.01.02.0030.002206%
Erythema23.03.06.001--Not Available
Extrasystoles02.03.02.0030.001471%Not Available
Eye disorder06.08.03.001--Not Available
Eye haemorrhage24.07.05.002; 06.07.02.001--Not Available
Eye pain06.08.03.002--
Eye swelling06.08.03.003--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Facial paralysis17.04.03.008--Not Available
Faeces discoloured07.01.03.002--Not Available
Failure to thrive19.07.05.001; 18.04.01.003; 14.03.02.0080.000384%Not Available
Fatigue08.01.01.0020.226531%
Febrile neutropenia08.05.02.004; 01.02.03.002--
Feeling abnormal08.01.09.014--Not Available
Fistula15.03.02.0010.001471%Not Available
Flank pain20.02.03.006; 15.03.04.003; 08.01.08.007--
Flatulence07.01.04.0020.008826%
Fluid overload14.05.06.001; 02.05.04.004--Not Available
Fluid retention20.01.02.003; 14.05.06.0020.022065%Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Fracture15.08.02.001; 12.04.02.0010.005884%
Frequent bowel movements07.02.04.002--Not Available
Gait disturbance17.02.05.016; 08.01.02.002--
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 22 Pages